Measles outbreak in Burkina Faso, 2009: A case–control study to determine risk factors and estimate vaccine effectiveness
Highlights
► We investigated a large (>54,000 cases) 2009 measles outbreak in Burkina Faso. ► In a case–control study, non-vaccination was the main risk factor for measles. ► Measles vaccine was effective in reducing risk of measles during the outbreak. ► Measles vaccination coverage was likely lower than reported national estimates. ► Main reasons provided for not receiving measles vaccination are described.
Introduction
Measles is a highly contagious disease associated with complications such as pneumonia, diarrhea, or encephalitis in approximately 30% of cases and case fatality ratios (CFRs) as high as 5–10% in developing countries [1], [2], [3], [4], [5]. In 2000, despite the availability of a safe and effective vaccine, measles caused an estimated 733,000 deaths worldwide; 371,000 (51%) of these were in Africa [6]. In 2001, the World Health Organization (WHO) Africa Region joined the global initiative to reduce measles deaths by 50% during 1999–2005 [6]. Strategies for measles mortality reduction recommended by WHO and United Nations Children's Fund (UNICEF) include (1) providing a first dose of measles vaccine to all children at age nine months or shortly after; (2) providing every child with a second opportunity to receive measles vaccine, either through a campaign or routine immunization; (3) establishing effective measles surveillance; and (4) improving measles case management [7]. Implementation of these strategies led to a significant decline in measles mortality globally and in Africa, where estimated measles deaths decreased 92%, from 371,000 to 28,000 during 2000–2008 [6].
However, further declines have been threatened by multiple outbreaks in Africa during 2009–2010, including a large outbreak in Burkina Faso in 2009 [8]. Burkina Faso, formerly Upper Volta, was one of the first countries to introduce measles vaccine and has conducted intermittent mass measles vaccination campaigns for children since the 1960s [9], [10], [11], [12], [13], [14], [15], [16]. Following the country's adoption of the WHO/UNICEF measles mortality reduction strategies, a nationwide “catch-up” campaign was conducted targeting children aged 9 months to 14 years in 2001 [17], and nationwide “follow-up” campaigns were conducted targeting children aged 9–59 months in 2004 and 2007. Based on post-campaign surveys, estimated coverage during these campaigns ranged from 96% to 97% nationwide [18], [19]. In addition to campaigns, routine measles immunization in Burkina Faso began in 1980 through the Expanded Programme on Immunization and consists of one dose of measles vaccine at age 9–11 months. WHO/UNICEF estimates of routine measles vaccination coverage have increased from 38% in 1985 to 75% during 2005–2008 (Fig. 1) [20].
Despite these immunization activities, Burkina Faso continued to experience periodic measles outbreaks, with a large outbreak in 2009. During May–August 2009, we conducted an investigation to describe the 2009 outbreak and outbreak response campaign, and a case–control study to determine risk factors for measles during the outbreak, estimate vaccine effectiveness (VE), and identify reasons for not receiving measles vaccination.
Section snippets
Field investigation
Measles vaccination coverage. Administrative estimates of vaccination coverage (number of doses administered by health care workers divided by the census-projected number of eligible children in the population) during routine immunization, previous immunization campaigns, and the 2009 outbreak response campaign were calculated using data provided by the Burkina Faso Ministry of Health (MOH).
Measles surveillance. Clinically diagnosed measles cases have been reportable to the Burkina Faso MOH
Measles epidemiology, 1996–2008
Before 2009, the largest documented measles epidemic in Burkina Faso occurred in 1996, with 32,415 reported cases (Fig. 1). During 1997–2005, annual outbreaks of 1077–8920 cases occurred, with peak transmission during January–June each year. In 2007, cases decreased to 150, an historic low. However, in 2008, cases increased to 1762 and transmission continued throughout the year and into 2009.
Measles outbreak, 2009
In total, 54,111 measles cases and 367 measles deaths were reported in 2009 through the aggregated
Discussion
Despite implementation of WHO-UNICEF measles mortality reduction strategies since 2001, including three nationwide immunization campaigns with >95% estimated coverage during 2001–2007 and increasing routine measles vaccination coverage, Burkina Faso experienced its largest measles outbreak on record in 2009. This outbreak was notable for its size and age distribution, with 35% of cases occurring in persons aged ≥15 years. The main risk factor for measles was lack of vaccination, and measles
Acknowledgments
This work was supported by the Burkina Faso Ministry of Health, World Health Organization (WHO), United Nations Children's Fund (UNICEF), and the United States Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. This investigation would not have been possible without the support of numerous people in Burkina Faso and elsewhere. The authors would particularly like
References (38)
- et al.
Measles vaccine
- et al.
Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study
Lancet
(2007) - et al.
Measles outbreak in Tanzania, 2006–2007
Vaccine
(2010) - et al.
The clinical significance of measles: a review
J Infect Dis
(2004) - et al.
Case-fatality rate during a measles outbreak in eastern Niger in 2003
Clin Infect Dis
(2006) - et al.
Estimates of measles case fatality ratios: a comprehensive review of community-based studies
Int J Epidemiol
(2009) Global measles mortality 2000–2008
MMWR
(2009)Measles mortality reduction and regional elimination strategic plan 2001–2005
(2001)Measles outbreaks and progress toward measles preelimination – African region, 2009–2010
MMWR
(2011)- et al.
Response of Volta children to jet inoculation of combined live measles, smallpox, and yellow fever vaccines
Bull World Health Organ
(1964)
Response of Volta children to live attenuated measles virus vaccine
Bull World Health Organ
Sentinel for health: a history of the Centers for Disease Control
Standardization and mass application of combined live measles-smallpox vaccine in Upper Volta
Am J Epidemiol
Lessons learned. Rapid assessment: vaccination commando Burkina Faso
Mass measles vaccination in urban Burkina Faso, 1998
Bull World Health Organ
Measles incidence before and after mass vaccination campaigns in Burkina Faso
J Infect Dis
Measles vaccination coverage during poliomyelitis national immunization days in Burkina Faso, 1999
J Infect Dis
Migration as a risk factor for measles after a mass vaccination campaign, Burkina Faso, 2002
Int J Epidemiol
Evaluation de la campagne nationale de vaccination de masse contre la rougeole et la polio décembre 2004 au Burkina Faso
Cited by (25)
Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh
2021, VaccineCitation Excerpt :An observational case-control design may represent a viable alternative strategy, which we estimate could be completed within 7 years, even with no investments to improve case detection. Case-control designs have been previously used to evaluate vaccine efficacy in the context of routine vaccination programs, as in the case of tuberculosis, meningococcus, measles and poliomyelitis vaccines [24–28]. A practical advantage of the case-control study design is that it may raise fewer ethical concerns for participants, as vaccination is not withheld from a part of the population that would have been vaccinated otherwise, and could therefore be more acceptable to communities.
High risk of subacute sclerosing panencephalitis following measles outbreaks in Georgia
2020, Clinical Microbiology and InfectionCitation Excerpt :These cohorts, with historically low coverage because of past problems with immunization services in Georgia, include substantial numbers of individuals who were not vaccinated in childhood and escaped infection until adulthood, as overall incidence of measles declined with the introduction of vaccines. As a result, in Georgia, similar to many other countries [8,12,25–28], measles cases are occurring at older ages. Young adults (aged 15–39 years) accounted for 39% and 55% of measles cases in the 2004–2005 and 2013–2015 outbreaks, respectively [8,12].
The effect of immunization on measles incidence in the Democratic Republic of Congo: Results from a model of surveillance data
2015, VaccineCitation Excerpt :It continues to be among the largest causes of vaccine-preventable disease mortality among children under five, despite the availability of a safe and efficacious vaccine [1]. While measles vaccine induces immunity that is effectively lifelong, vaccine efficacy is expected to be 85% at 9–11 months of age and increases to 95% at ≥12 months [2–4]. Prior to vaccine licensure, measles caused an estimated two million deaths and more than 15,000 cases of blindness worldwide each year [5].
Field evaluation of measles vaccine effectiveness among children in the Democratic Republic of Congo
2015, VaccineCitation Excerpt :While our analyses for VE were restricted to a younger age group, a large proportion of the confirmed measles cases were seen in older age categories, suggesting a history of immunization deficiencies in DRC. Measles vaccine efficacy is expected to be 85% following the first dose at 9 to 11 months of age and 95% after the second dose at ≥12 months [25,27]. Given the study population of children aged 12 to 59 months; the subjects were more likely to be exposed to more than one dose of MCV either through routine immunization and SIAs, suggesting that failure rates should be low.
Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso-Implications for introduction of PsA-TT into the Expanded Programme on Immunization
2015, VaccineCitation Excerpt :Even with Burkina Faso's high-performing immunization program, which achieved a remarkable increase in reported routine MCV coverage from 48% in 2000 to 92% in 2010 and multiple years with SIA coverage >95% [17], the country experienced its largest ever recorded measles epidemic in 2009 with over 54,000 cases. Non-vaccination, likely longstanding as evidenced by the high disease rates in adolescents and adults, was identified as the greatest risk factor [18]. These challenges highlight the need for support for immunization programs with careful monitoring of vaccine introduction and strong surveillance systems to ensure sustained high coverage and rapid identification of gaps in population immunity.
Moving forward with strengthening routine immunization delivery as part of measles and rubella elimination activities
2013, VaccineCitation Excerpt :In the Africa region, however, the reductions by 93% and 91% in measles cases and measles-related mortality, respectively, was followed by a resurgence of confirmed outbreaks in 61% of countries in the region, despite reported high levels of MCV1 and SIA coverage [17,18]. Investigations indicated that non-vaccination (either through routine immunization or SIAs) was the major reason for outbreaks, with vaccine unavailability, delays in vaccination, lack of understanding of importance of immunization, and unwillingness among certain religious groups to permit vaccination of their children as underlying causes [17,19]. This experience highlights the importance of making the most effective use possible of complementary service delivery strategies to prevent measles, particularly in settings with limited infrastructure and human resources.
- 1
Present address: Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, United States.